Details

Autor(en) / Beteiligte

• Hoepner, Robert
• Kamm, Christian P
• Friedli, Christoph
• Salmen, Anke
• Chan, Andrew

Titel

Is COVID‐19 severity associated with reduction in T lymphocytes in anti‐CD20‐treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

Ist Teil von

• CNS neuroscience & therapeutics, 2022-06, Vol.28 (6), p.971-973

Ort / Verlag

England: John Wiley & Sons, Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In total, 14 patients with multiple sclerosis (MS, 11/14) or neuromyelitis optica spectrum disorder (NMOSD 3/14) receiving anti-CD20 drugs, who had a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2) infection while on anti-CD20 treatment, were identified by medical chart review (Cantonal Hospital Lucerne: 5/14, ethic vote: 2020–00044; University Hospital Bern 9/14, NI registry ethic vote: 2017–01369, last amendment August 2020). Abbreviations: COVID-19, Corona Virus Disease-19, EDSS, Expanded Disability Status Scale, FACS, fluorescence-activated cell sorting, ICU, intensive care unit, MS, multiple sclerosis, NMOSD, neuromyelitis optica spectrum disorder, PPMS, primary progressive MS, RMS, relapsing MS Our small case series did not demonstrate differences in T lymphocyte populations between hospitalized and non-hospitalized patients with COVID-19 during anti-CD20 treatment. [...]a study of our group, focusing on patients with any autoimmune disease treated with anti-CD20 medications and being listed in the FDA Adverse Event Reporting System, confirmed a higher risk of death due to COVID-19 in anti-CD20-treated patients (OR 4.5 95%CI 2.6–7.9) even after adjustment for the local dynamics of the pandemic and the performance of the national health care system. 1 However, despite the known patient-related risk factors such as age and ambulatory disability, 7 anti-CD20 treatment-related risk factors such as reduction in T cell counts are still unknown justifying our small case series and hopefully stimulating further research in this field.